An evaluation of two years of clinical experience with ketoconazole.
D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000188:drug therapy; D002862:Chromoblastomycosis / Q000188:drug therapy; D003047:Coccidioidomycosis / Q000188:drug therapy; D003881:Dermatomycoses / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D006660:Histoplasmosis / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007654:Ketoconazole; D009181:Mycoses / Q000188:drug therapy; D014009:Onychomycosis / Q000188:drug therapy; D010229:Paracoccidioidomycosis / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D010915:Pityriasis / Q000188:drug therapy
D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole